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Expression and surface assembly ofantigen receptors occurduring the differenti-
ation of lymphoid progenitors into mature B and Tlymphocytes, endowing each
lymphocyte with a unique antigen recognition capacity. The specific polymorphic
antigen binding structure on B lymphocytes is surface Ig, while the CD3Ti TCR
subserves that purpose on T cells (1-3). The latter is a heterodimeric structure non-
covalently associated with monomorphic CD3 subunits ('Y, S, E, and ~), which as-
semble on the surface of T cells and interact with foreign antigens in association
with MHC molecules.
From prior studies it has been shown that the assembly of Ig genes takes place
early in B cell development (4) in an ordered fashion, culminating in the rearrange-
ment and expression ofH chain genes (5), and subsequently, L chain genes (6-8),
so that a functional Ig molecule is produced. The molecular architecture ofthe Ig
Hchain (IgH) and L chain (IgL) loci has been intensively studied (9). Transfection
analysis of both IgH and IgL genes revealed an element in addition to the VH or
V promoters that contributed to the expression ofthese genes. The latter has been
generally referred to as an enhancer, which was shown to possess similar properties
to the well-described viral enhancer elements (10). This element was shown to be
located in the major intron between the J region and the Cp or Ck genes (11-15).
More recently, the TCR loci have been characterized, and the genes encoding
theTi antigen/MHC binding subunits present on the majority(95%) ofperipheral
T lymphocytes (a and 0), as well as those encoding surface receptors (,y and 6) on
a minorpopulation (5%), have been cloned. One majorconclusion from those studies
is that the organization of IgH and TCR genes that are composed ofmultiple V
D, J, and C segments (except TCR-a) is very similar in both mouse and human
(16, 17). To define elements that confer a strict tissue specificity to the expression
ofthe /3 subunit ofthe TCR, we have begun an analysis of a TCR V region gene
promoter. This analysis will aid in the understanding ofthe molecular basis for T
lineage differentiation and serve as a first step in identifying nuclear factors that
bind to the DNA elements that we have characterized.
In this report we show that the promoter ofa functionally rearrangement Va gene
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(V,Q8.1; references 18-20) acts in a tissue-specific manner upon transfection anal-
ysis. Additionally, we present evidence for a strong upstream element of 230 bp,
which is active in either orientation in conferring to a heterologous promoter, T
cell-specific expression. No previously characterized expression element or transcrip-
tion factor binding site was localized in this region of the promoter, including those
sequences responsible in part for cell-specific expression of Ig genes.
Of considerable importance is the additional finding that the V'38 promoter is non-
functional in B cells, the most closely related hematopoietic cell type to T cells. Our
transfection results point to the promoter as a restricting element in the T lineage
expression of the V#83 gene, which is consistent with the observation that rearranged
or germline configured V0 or V genes are not expressed in the inappropriate cell
type. Since we and others (21, 22) find no enhancer element equivalent to the Ig
expression enhancer in the major intron between the J region and C31, it is likely
that the Vp promoter plays a key role in tissue-specific expression of the /3 chain
of the TCR .
Materials and Methods
Cells and Media.
￿
The human cell lines Jurkat subline 77 (a gift of G. Crabtree, Stanford
Medical School) and JY (a gift of T. Springer, Harvard Medical School) were cultured in
RPMI 1640 (Gibco Laboratories, Grand Island, NY) and 10% FCS (Flow Laboratories, Inc.,
McLean, VA) supplemented with penicillin-streptomycin (Gibco Laboratories) and gluta-
mine (Gibco Laboratories). Murine cell lines EL-4 (a gift ofT. Taniguchi, Osaka University)
and J558 (American Type Culture Collection, Rockville, MD) were grown, respectively, in
RPMI 1640 (Gibco Laboratories) and DMEM (Gibco Laboratories) supplemented identi-
cally as in the case of human cells. Fibroblasts of human (Hela; a gift of P. Sharpe, M . I . T.)
and monkey origin (Cos; a gift of B. Seed, Harvard Medical School) were cultured in DMEM
(Gibco Laboratories) and supplemented as described above.
Plasmid Construction.
￿
The charon 30 phage X/33 (23) was cleaved with the enzyme Sma
HI, and a 3.5-kb fragment containing the Vp8.1 gene was identified by hybridization. The
subcloned DNA in pUC 12 was further cleaved using Bgl II and Xba I and subcloned into
the expression vector pOCAT2 (a gift of D. Moore, Harvard Medical School; reference 24).
A series of deletions was generated by restriction enzyme digestion, which are referred to
with the prefix BP800, BP570, etc. Their derivation is shown in Table I . Plasmids that con-
tain the 309-bp fragment containing the RSV enhancer (25) 5' of the inserted promoter also
contain the prefix R such as in RBP800 (see Table I). Plasmids with the prefix IgHE (H
chain enhancer) contain the 1.0-kb Xba I fragment derived from PSV2 'Y2bVC (12), and are
described more fully in Table 1 .
An additional set of plasmids were made using the expression vector pUTKAT (a gift of
D. Moore; reference 24), which contains the 250-bp herpes simplex thymidine kinase pro-
moter fragment (TK;' reference 26). The largest of these BT800s was derived by cleaving
the 817-bp Xba I to Bgl II Va8.1 promoter fragment with Nsi I at -45 (Fig. 1 B), filling
in the ends with four deoxynucleotide triphosphates and the klenow fragment of DNA poly-
merase 1, and subsequent ligation to Xba I cleaved and filled in pUTKAT. The remainder
of the V,38.1 upstream DNATK promoter fusion plasmids (BT800, BT570, etc.) are described
in Table I . Similarly, pUTKAT derivatives containing either the RSV enhancer fragment
(RTK) or the IgHE fragment (IgHETK) are so designated .
Plasmids in which the deletions created are internal are designated with the 5' and 3' bound-
aries of the deletion (i.e., BT or BP 8051, see Table I). The BP prefix indicates a 3' boundary
' Abbreviations used in this paper: CAT, chloramphenicol acetyl-transferase; COE, CO enhancer; RT, room
temperature; TK, thymidine kinase; TPE, T cell promoter element.DIAMOND ET AL.
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at +17, while the BT prefix indicates a 3' boundary at -45, unless designated otherwise (Table
I and Fig. 5).
Transfection Analysis.
￿
Lymphoid cells were transfected with plasmid DNA by a modification
of Fujita et al. (27). Briefly, suspensioncells (Jurkat, JY, J558) were adjusted to a concentra-
tion of 3 x 105 with fresh medium for 12-16 h before transfection. 1 .5 x 10' cells were
pelletted, then washed with 1 x transfection buffer (27), and resuspended in transfection buffer
and DEAE-dextran (J77, 500 ug/ml;JY andJ558, 300 Ftg/ml) with DNA (20 l~g/ml) in 1 ml.
The concentration of DEAE-Dextran that gave the most efficient conversion of '4C-chlor-
amphenicol (see below) was used in each case. In the case ofJ77 and J558, after a period
of 90 min at 37°C (resuspension every 30 min), 0.1 ml DMSO was added and the cells were
further incubated at room temperature (RT) for 3 min. The cells were then diluted in 10 ml
of 1 x transfection buffer, pelleted at 1,200 rpm, and further washed with RPMI 1640 without
serum. The washed and pelleted cells were then resuspended in 10 ml of complete medium,
and incubated for -40 h at 37°C.
A slightly modified method of DEAE-dextran-mediated transfection was used for EL-4
cells. Since the subline ofcells we used attached to plastic (tissue culture 100 x 20-mm plates,
Falcon Labware, Oxnard, CA), the transfection took place directly on the plates. 12-16 h
before the transfection, cells were detached from large flasks by a 5' treatment with PBS-
EDTA (0.6 mM, pH 8.0) at 37°C, and ti3 x 106 cells were plated on the 100 x 20-mm dish
in fresh medium. The medium was aspirated, and the plates washed with transfection buffer,
then 2.5 ml of a solution of 100 wg/ml DEAE-dextran and 8 hg/ml plasmid DNA in transfec-
tion buffer was applied for 30-60 min. The plates were subsequently washed with 10 ml of
transfection buffer followed by serum-free RPMI 1640. The cells were incubated for 2 d in
10 ml of fresh complete medium.
Transfection of fibroblasts using CaP04, (L, Hela, Cos) was done according to established
methods using 5 l~g of DNA per 100-mm dish containing 7.5 x 105 cells (28).
Chloramphenicol Acetyl-transferase (CAT) Assay.
￿
Cells were harvested by centrifugation (sus-
pension) or by previous treatment with PBS-EDTA (adherent), then washed two times in
PBS. Freeze-thaw lysis in 0.25 M Tris HCL, pH 7 .4, and subsequent assays were done ac-
cording to Gorman et al. (29) using "C-chloramphenicol (0.2 ACi at 40-60 Ci/mol; New
England Nuclear, Boston, MA)) and 0.8 mM acetyl-coenzyme A (Sigma Chemical Co., St.
Louis, MO). The time of assay varied depending on the cell line (Jurkat, EL-4, and J558,
6 h; JY, Hela, and Cos, 1-2 h). A 10-min incubation of certain extracts at 60°C inactivated
an activity (presumably a de-acetylase), which enhanced the conversion of chloramphenicol
to its acetylated forms. This effect was proportional to the activity before inactivation, and
therefore, did not change the relative activitiesofthe test plasmids. Every experimental plasmid
was tested in duplicate in three or more separate transfections with each cell line. The various
forms of acetylated chloramphenicol were quantitated by excising the radioactive spots and
scintillation counting in Betafluour (New England Nuclear).
S1 and RNAse Protection.
￿
Sl probes (shown in Fig. 2 A), and subsequent hybridization
and protection methods were done according to Diamond and Goodman (30). Maxam-Gilbert
sequencing of the end-labeled probe was done according to Maniatis et al. (31). Products
ofthe S1 and sequencing reactions were subjected to electrophoresis on 8% polyacrylamide/8 M
urea gels. The gels were autoradiographed at -70°C with Cronex Lightning Plus intensi-
fying screens (DuPont Co., Wilmington, DE).
For RNAse protection, an Nco I fragment (600 bp) encompassing the Y ,e83 promoter
proximal sequences from pVsf (see Table I) was subcloned at the Sma HI site by blunt-end
ligation into ptz19R (United States Biochemical Corp., Cleveland, OH) in both orientations.
The plasmid ptzV0 was linearized with Eco RI, and after purification was resuspended in
10 mM Tris and 1 mM EDTA, pH 8.0 (TE), at 1 mg/ml. Labeled ssRNA transcripts were
prepared as described (32), and hybridization protection was carried out according to Melton
et al. (33). The reaction products were subjected to electrophoresis on an 8% polyacrylamide/
8 M urea gel along size end-labeled pUC 12 Hpa II-digested size markers.
Miscellaneous Techniques.
￿
Plasmids were purified two times over CsCl ethidium-bromide
gradients, and in every case the structure of the plasmid was verified by extensive restriction
enzyme digestion. In many cases the boundaries of the newly inserted fragment were se-121 6
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quenced to verify orientation and the identity of the insert. The 855 by of the 5' end and
flanking sequences of the V68.1 gene were sequenced on both strands by the Sanger method
of dideoxynucleotide termination sequencing.
Protein concentration was measured using the Bio-Rad protein assay reagent (Bio-Rad
Laboratories, Richmond, CA). Each sample in a particular assay contained the identical
amount of protein, although between experiments the amount of protein varied.
Results
Sequence Analysis ofa V,88.1 Promoter.
￿
The sequence of the V,88.1 promoter is shown
in Fig. 1 A, where several important sequence motifs are underlined. Examination
of the proximal sequence (with respect to mRNA start site) reveals two potential
transcription factor binding sites, the CCAAT box (34, 35) at -149 and apresump-
tive AP-1 bindingsite (-69 to -53;reference 36). Within the latter lies adecanucleotide
(AGTGA TCA) of unknown function found in 13 of 14 Vg promoters examined (37).
However, detailed comparisons of the upstream sequence (+1 to -800) of the V,88.1
promoter with other TCR V andVO promoters failed to show any striking sequence
similarities (use of the local program; reference 38). This is not surprising, since
a comparisonn of Ig V promoters (39) revealed only a striking similarity at the po-
sition of the octamer and TATA motif (40, 41).
In a further sequence comparison with a region downstream of C,82 identified by
Krimpenfoort et al. (21) to be a regulatory element for TCR (3 chain transcription
(CO enhancer; COE), we found only limited areas of close sequence similarity. How-
ever, certain stretches of sequence showed near identical patterns at several different
positions (Vp, -669 to -680/CRE, 812-822 10/11; VR, -752 to -761/CQE, 890-899
10/10; Va, -225 to -239/COE 479-483 14/14 plus two gaps; Va, -751 to -771/COE,
471-491 18/18 plus four gaps). Numbering of VO promoter according to Fig. 1 A
and COE according to Krimpenfoort et al. (21).
SI Mapping Reveals Location ofProximal Transcription Signals.
￿
To determine thetran-
scriptional start site and signals for the V,88.1 promoter in Jurkat cells, we performed
protection studies using cytoplasmic RNA from a variety of cells and analyzed the
products on 8% polyacrylamide/8 M urea gels along side a partial Maxam-Gilbert
sequencing ladder as shown by the autoradiograph of the gel in Fig. 2A. The Sl-pro-
tected fragment of 55 by aligns with a C residue 29 by downstream of a Goldberg-
Hogness box (GATA; reference 41). The protected fragment is of the identical size
in the T cell lines Jurkat andJM, both of which express the V,88.1 gene (Fig. 2 B,
lanes 1 and 2), although it is not present in another T cell clone, RFL 3.51 (Fig.
2, lane 3), which utilizes aVO segment from a different family (V,82.3; unpublished
results). Given that the assay is accurate to within ±1 by and adenosine is a favored
base for eukaryotic transcription initiation (41), we have placed the start at the A
(+1) as shown. We confirmed this finding by using the technique of RNase protec-
tion of a 32p complementary RNA probe and the same RNA samples as in Fig.
2 B (Fig. 2 C, lanes 8-11). Note, as expected, use of a sense ssRNA probe failed
to yield a protected fragment (Figure 2 C, lanes 3-6).
The 0. 8-kb V,88.1 Promoter Fragment Is Sufficientfor T Cell Expression. To characterize
the V,88.1 promoter further we used the properties of theheterologous reporter gene
(CAT) to analyze expression in a variety of cultured cells. We subcloned 820 by
of the 5' flanking sequence betweenthe XbaI site at +20 and theBgl 11 site at -800
into the pOCAT vector (24) upstream ofthe CAT coding sequence (Fig. 3 A) . TheseB
-800
GATCTTTCTC TCAGCTTTCC ATAATCTCTG AGCGAAGTAC GTTTGGAGAA CTGGGGTTAC
-740
AGGGGAAAAA GCCAGGTGTT AATGATGAAA AAACATTCAA CTTTTCTACC GCTACTAATA
-680
ACATTTAATT CAAGTACTGA GAACATTTAC CTCAAATCTT CAAGAATAAG ACAATATTAT
-620
CCCCTTTCTC TTTTATTGTC GGACTAGAGA ATGTGAGAGA GGTTACATTC CATGGGCTTT
-560
GGGAATTTAA TATGGTTCAA GGATAAACAC ACCCAGGTTT TTCACTCCAG AGAAGAGCTT
-500
CAAATATAAT CCAGTTTTCA GGTCATCAGC TCAGCTCTTG TATCCCTAAC AATGCGGTTG
-440
ACATACCGTC TTCTCACATA GTCTAAACTC CTAAACTCAC TAAGCCATAC TTTAAAGTAC
-380
ATATAAAGGA CTAGAAGCAC CAAGCTACCA GTGAGACGAA GAGGAGAGTT TCCACAGAAG
-320
CTGGCTTCAA ATAAGACAAT GAGTTCATCT TTAAATACTT GCCATTTGAG GTGCAGATGG
-260
ATATAGTTGG CAGGCTCCTA TCTAACGCAT GTTATGCACA AGCTACCGTG AATTGATAAT
-200
ATCAAAACAA ATATCCAGCG AGCCTCTGCA AGTGTGCATC TCTATTTCAC ACCAATTATA
-140
GTTGACTTAA TTCCTCCCTC ATTCATCTCC CAGAGATGCA GCCTCCTCTT AAAGAAGTTG
-80
CGGCTGGTGG CCCATTCAGT GATGTCACTG ACAGATGCAT TCTCTGGGQA J&AAATGTCA
-20
￿
+1
CAAAATTCAT TTCTTTGCTC QTGCTCACAG AGGGCCTCGT CTAGAATATT CCACATCTGC
+41
TCTCACTCTG CCATG
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(A) Sequence of the 5' flanking DNA of the V0.1 promoter. Underlined sequences
arediscussedin the text. +1 indicates theputative start site formRNA synthesis. However, the
upstream C wasdetermined experimentally in this paper(Fig. 2). TheAat +53 is thefirst base
of the initiator methionine residue within the leader protion of the TCR 0 chain protein. (B)
Restriction map of the rearranged V,88.1 segmentsubclonedfrom phageDNA. pVgJ 3 is described
in Table I. The abbreviations for the restriction endonucleases are as follows: Bg1, Bgl II; H,
Hinc II; N, Nco I; Ni, NsiI; R, RsaI; S, Sma I; X, XbaI; Xm, Xmn I. The boxes that contain
letters representtheleaderexon (L), first intron (I), variable segment(V), diversity segment (D),
andjoining segment (J), whichcomprise amature Vß gene segment. These sequence data have
been submitted to the EMBL/GenBank Data Libraries under the accession number Y00797.1218
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FIGURE 2 .
￿
Sl and RNase protection analysis of cellularRNA by the exon containing the LDNA
segment of the V,68 .1 V gene . (A)Mapofthe region used in the protection analysis . The striped
bar represents the fragment either double stranded (Sl) or single stranded (RNase), which was
radioactively end (Sl) or uniformly labeled (RNase), and hybridized to cellular RNAs . Num-
bering is identical to Fig . 1 A, and symbols are defined exactly as in Fig . 1 B . The darkened
box represents the protected region of the probe after hybridizationandenzymatic cleavage . (B)
Results of Sl analysis ofRNA from Jurkat (lane 1),JM (lane 2), RFL 3.51 (lane 3), yeast (lane
4) cell, To the left of lanes 1 and2are shown the results ofMaxam-Gilbert sequencing reactions
on the end-labeled probe used in the RNA protection analysis (SI) . Shown in lane 6 are Hpa
II-digested and end-labeled pUC 12 molecular weight markers, whose sizes are defined on the
extreme right in base pairs. The sequence of the indicated region containing the transcriptional
start site is shownon the left as determined in Fig . 1A .Pcorresponds to the labeled hybridization
probe, and Fr indicates the protected fragment . (C) Results ofRNase protection ofcellular RNAs
fromJurkat (lanes 6 and 11), JM (lanes 5and 10), EL-4 (lanes 4 and 9), and yeast RNA (lanes
3and 8) usinganssRNAprobe that wasgeneratedfrom the sense (lanes 1-5) or antisense (lanes
6-11) strand from the plasmid ptzVg0or its reverse ptzVg0' (Table I) . Shown in lanes 1 and 12
are end-labeled and Hpa 11-digested pUC 12 DNA molecular weight markers .DIAMOND ET AL.
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FIGURE 3 .
￿
(A) Expression vec-
tors used in the analysis of
the V68.1 promoter. Prost and
Moore (24) have describedpUC
12 derivatives that can accept
either proximal promoter frag-
ments(pOCAT1) or distal pro-
moter fragments using the TK
promoter proximal signals
(pUTKATI) . The TKmRNA
3' untranslated region was fused
to theCATgene to provide a eu-
karyotic polyadenylation signal
sequence. (B) Results of trans-
fection of several V,68 .1 pro-
moter plasmids into EL-4 cells .
As described in Materials and
Methods, aCAT assay was per-
formed for6 h, and the products
that were separated on TLC
plates were analyzed by scinti-
lation counting andquantitated
as shown in Fig. 5 A . Plasmids
transfected are the full-length
promoter fragment, BP800
(lanes 1 and 2), ABP800 (lanes
3 and 4), BP045 (lanes 5 and
6), pUTKAT (lanes 7and 8),
RBP800 (lanes 9and 10), and
ARBP800 (lanes 11 and 12) .
plasmids were transfected using DEAE-dextran (see Materials and Methods) into
EL-4 (a murineT cell tumor) and Jurkat (human T cell tumor; data not shown)
cells . As shown in Fig . 3 B (lanes 1 and 2 vs . 7 and 8) it is clear that the BP800
plasmid stimulates greater CAT activity in T cells than pUTKAT, which contains
the TK promoter.
To further define the sequences necessary forT cell-specificVa promoter activity,
a series of 5'-3' deletions were constructed and assayed in both Jurkat and EL-4
cells .2 A schematic illustrating the structure of these deletions as well as the others
presented in this report are shown in Fig. 4, A andB. This deletion series demon-
strates that the majority of the promoter activity resides upstream of -350, pre-
dominantly between -800 and -510 (Fig . 4A) . In fact, an internal deletion of se-
quences between -510 and -45, which leaves the upstream sequences intact, results
in a plasmid with T cell Va promoter activity equivalent to the intact promoter
plasmid BP800 (Fig. 4 A) .
Deletion of Transcriptional Start Siteand Upstream GATA Sequence Abrogates Transcription
from the V,68.1 Promoter . To determine whether theCAT protein acetylating activity
resulted from mRNA that was initiated in plasmid BP800 using the endogenous
z We have subsequently found the murine line to be more active for Vs8 promoter-stimulatedCAT
activity than most human cell lines (JM, REX, HBPALL ; data not shown), so that the effect ofdeletions
that reduce the strength of the promoter are more easily seen in EL-4 than in Jurkat cells. However,
the relative effects of the deletions are identical between EL-4 andJurkat, as presented in the data on
Jurkat transfections shown in tabular form.1220
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29
-570
-510
-450
150bp
TK
Vector
￿
Fold A
￿
-DNA
￿
Plasmid
￿
Acetylation (x)
pUTKAT L0
BP800 5.0
BP570 3,5
-_--~ BP510
￿
2.5
-J ￿~
￿
- . -
￿
BP450
￿
2.0
-350
￿
BP350 1.0
-45 BP045 0.5
ABP800 <0.1
-450 -45 BP8045 2.0
-510
￿
-45 BP8051 5.0
-445
J-445
-510
-570
-800
"84'id!' 'I' -635
200bp
TK
TK
TK
pUTKAT 1 .0
BT800 2,0
BT'800 8,0
BT570 2.5
BT445 2.2
878044 1.2
878051 10.0
878057 10.0
BT'8057 8.0
878057/30 6.0
878063 4.0
FIGURE 4
￿
Summary ofactivities of the deletedformsofthe Y,68.1 promoter in Tcells. (A) Shown
are plasmids that were tested in both EL-4 andJurkat cellsaminimum of three separate times.
Derivation of each plasmid is shown in Table I, with V$ promoter region sequences stippled.
The fold acetylation quantities were determined by averaging the results of each replicate after
quantitation by scintillation counting. The variation between experiments did notexceed 20%.
The fold differences shown are forEL-4 transfections, and are applicable to theJurkat cell line,
except that the activity of the Y,68.1 promoter-containingplasmids are reduced by a factor of
two. (B) Same as Fig. 4A, except the plasmids compared areall derivatives of the TK promoter
fused with upstream fragments of the Y,g8.1 promoter. Derivation of each plasmid is shown in
Table I.
start site (determined above), we excised the proximal promoter sequences using
the combination of Nsi I and Xba I digestion (Fig. 1 B and Table I). This deletion
plasmid (OBP800) was transfected into Jurkat and EL-4 cells along with another
deletion plasmid(ORBP800) similarly prepared, which contains the RSV enhancer
(Fig. 3BandTableI). Note that essentially no CATactivity arises from these plasmids,
as compared with the undeleted plasmids shown in Fig. 3 B (lanes 3 and 4, 11 and
12 vs. 1 and 2, 9and 10). A deletion from -800 to -45 did not completely abolishDIAMOND ET AL.
TABLE I
Derivation of Plasmids Used in this Study
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Plasmid Method of construction
pOCAT (24)
pUTKAT (24); contains the TK promoter in the polylinker as a 250-bp Hinc II fragment.
RTK RSV LTR fragment (309 bp), ends blunted using Klenow and four deoxynucleotide tri-
phosphates, Barn HI linkers attached, cloned into the polylinker of pUTKAT.
IgHETK PSV2'y2t,VC digested with Xba I, the 1 .0-kb fragment blunt ended with Klenow, cloned
into the Xba I site of pUTKAT.
PVg0 OX03 digested with Sma HI, subcloned into the Sma HI site of pUC 12.
ptzVgf Isolate 600-bp Nco I fragment from pVga, blunt end, ligate to Sma HI cleaved ptz19R.
BP800 pV,,O was digested with Bgl II and Xba I, the 817-bp fragment cloned into the polylinker
of pOCAT.
IgHEBP800 IgHETK digested with Hinc II to remove TK promoter, the Bgl II-Xba I fragment from
pV;/3 was blunt ended, and ligated into the Hinc II site.
RBP800 The Xba I-Bgl II fragment was ligated to Xba I-digested pOCAT. The 309-bp Bam HI
fragment from pRTK was ligated to the Bgl II end of the promoter fragment, Barn HI
cut back ofmultiple inserts and digestion of polylinker, was followed by isolation of the
linear plasmid over agarose, and subsequent ligation gave the expected product.
BP570 pVgl6 digested with Nco I and Xba I, the 587-bp fragment was blunt ended with Klenow
and cloned into pUTKAT.
BP510 BP800 was partially digested with Xmn I and completely with Sac I, the ends were made
blunt with Klenow, and the plasmid was closed by ligation .
BP450 BP800 was digested with Hinc II, and the 467-bp fragment was subcloned into pOCAT
at the Hinc 11 site.
BP350 The Bgl II-Xba I fragment from pVgO was digested with Rsa I, and cloned into pOCAT,
which was partially digested with Sma HI and completely with Xba I.
BP045 BP800 was digested with Sac I and Nsi I to remove the internal 755-bp fragment, and the
plasmid was closed by ligation.
ABP800 BP800 or RBP800 was digested with Xba I and Nsi I to remove a 72-bp fragment, made
ORBP800 blunt with Klenow, and closed by ligation .
BP8045 BP800 was digested with Nsi I and partially with Hinc II to remove a 405-bp fragment,
the ends were blunted, and the plasmid closed by ligation.
BP8051 BP800 was digested completely with Nsi I and partially with Xmn I to remove an internal
455-bp fragment, the ends were blunted, and the plasmid closed by ligation.
BT800 Isolate the Nsi I-Bgl II fragment from pV,,O, blunt end, and ligate to Xba I-digested and
BT'800 blunt-ended pUTKAT.
BT570 Isolate the Nco I-Nsi I fragment of PB800, and ligate it to Xba I-digested and blunt-ended
pUTKAT.
BT445 Isolate the Hine II-Nsi I fragment from BP800, blunt end, and ligate it to Xba I-digested
and blunt-ended pUTKAT.
BT8044 Isolate the Bgl II-Hinc II fragment from BP800, blunt end, ligate to blunt-ended and Xba
I-digested pUTKAT.
BT8051 Isolate the Bgl II-Xmn I fragment from BP800 blunt end, and ligate to blunt-ended and
Xba I-digested pUTKAT .
BT8057 Isolate the Bgl II-Nco I fragment of BP800, blunt end, and ligate to blunt-ended and
BT'8057 Xba I-digested pUTKAT.
BT8057/P30 Isolate the 300-bp Rsa 1-digested fragment from pUC12, ligate it to Sal I-digested and blunt-
ended BT8057.
BT8063 Isolate the Bgl II-Ssp I fragment of BP800, blunt end, and ligate to Xba I-digested and
blunt-ended pUTKAT.1222
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CAT activity (Fig. 3 B, lanes 5 and 6) as compared with the ABP800 plasmid (Fig .
3 B, lanes 3 and 4) . Collectively, these results suggest that the initiation site we ex-
perimentally determined (Fig. 2 B) is correct, and presumably utilized in the plasmids
described here .
V,68 .1TK Promoter Fusion Plasmids Are Active in T Cells.
￿
The identification of a dis-
crete region containingT cell promoter activity lead us to constructa series ofplasmids
using the upstream region of the V,e8.1 promoter beyond -5 fused to theTK pro-
moter in the plasmid pUTKAT (Table I and Figure 4 B) . Theseplasmids were trans-
fected into bothJurkat and the EL-4 cell line (Fig. 4B) .Asurprising result occurred
when we examined the results of transfection analysis of plasmids containing se-
quences between -800 and -570 fused in either orientation to the TK promoter
in pUTKAT as shown in Fig . 5, lanes 1-4, and summarized in Fig . 4B. There is
little difference in theCAT activities generatedby plasmids with the 230-bp 5' flanking
sequence in either orientation, although the stimulation abovepUTKAT is 10-fold
when the V08 promoter upstream fragment is in the natural orientation (Fig. 5, lanes
1 and2 vs . 7and 8) . The addition ofa300-bp Rsa 1 fragment from pUC 12 between
theTK promoter and the V,B8.1 promoter 5' flanking sequence only slightly decreases
its abilityto stimulate CAT activity (Fig . 5, lanes 5and 6) . Further truncation (frag-
ment -800 to -635 ; Fig. 4 B) reduces the CAT activity, suggesting that we have
entered an important segment of the 230-bp fragment . Since we have not made ad-
ditional 3' deletions of the Vp promoter fragment, the precise 5' boundary of the
upstream element is still unknown . These results provide evidence for aT cell pro-
moter element (TPE) contained within the 230-bp upstream sequence of the Va8
promoter.
It is striking that the precise deletion of 60 by between -450 and -510 (compare
BP8045 vs . BP8051 orBT8044 vs . BT8051 in Fig. 4) activates the proximal sequences
of either TK or the V08 promoter. The molecular basis for the negative activity of
this sequence is not understood, although its activity is equivalent within the con-
text of the V08 orTK promoter proximal DNA (Fig . 4) . A further point is that the
interaction of the -45 to -800 fragment with its natural proximal sequence (V08)
is more efficient than when it is apposed to the TK promoter (Fig. 4, A and B) .
Presumably, certain sequence-specific alignments ofDNA elements aremore produc-
FIGURE 5 .
￿
Upstream 230-bp fragment confers
T cell activation on the TK promoter. Methods
oftransfection (legend to Fig. 3 A) andCAT anal-
ysis were done on EL-4 cells as previously de-
scribed . The plasmids transfected are BT8057
(lanes 1 and 2), BT'8057 (lanes 3 and 4), BT
8057/30 (lanes 5 and 6), and pUTKAT (lanes 7
and 8) .DIAMOND ET AL .
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FIGURE 6 .
￿
Expression of V,g8.1
promoter plasmids in Cos cells .
Transfection andCAT assays for
adherent cells are described in
Materials and Methods . Simi-
lar results were obtained for
Hela cells (data not shown) .
Plasmids transfected are pRTK
(lanes 1 and 2), BT8044 (lanes
3 and 4), BT8057 (lanes 5 and
6), BP800 (lanes 7 and 8), and
pUTKAT (lanes 9 and 10) .
tive in the context of the V08 promoter elements, which is not unlike the situation
with other tissue-specific promoters, including IFN-,!j (42) .
Transfection of V,38.1 Promoter Pasmids into Nonlymbhoid Cells.
￿
The foregoing experi-
ments have demonstrated that flanking DNA from the V,68.1 promoter stimulate
the TK promoter in T cells, however, the tissue specificity of this effect has not yet
been defined . Therefore, we transfected plasmids that showed the highest activity
in T cells into several fibroblasts' cell lines (COS and Hela cells ; Fig. 6 and Table
II) using CaP04 (27) . The results demonstrate that plasmids that contain either
proximal or upstream VF8.1 promoter elements such as BP800 (Fig . 6, lanes 7 and
8) or BP8051 (Table II) are inactive with respect to TPE activity in fibroblasts .
At the same time, we tested a series of V,88.1TK promoter fusion plasmids in
fibroblasts using CaP04 transfection . If we compare in each case the activity of a
fusion plasmid containing upstream V,88.1 promoter flanking DNA to the parental
TK promoter plasmid, it is clear that in fibroblasts, no increase in CAT activity
can be detected (Fig. 6, lanes3-6 vs . 9-10and Table II) . The small amount ofCAT
activity observed with BP plasmids may be attributed to the presence of basal tran-
scriptional elements such as a putative CAAT box, AP-1 recognition site, and the
universal TATA element (see Fig . 1 A) . Experiments with the IL-2 promoter using
this vector system reveal a similar basal CAT activity in all cells tested (data not
TABLE II
Quantitative Analysis of CAT Assay Results fiom Transfected
VB8.1 Promoter Plasmids in Fibroblasts and B Cells
Results shown are the mean of four separate transfections . Each cell type was
transfected with plasmids separately in duplicate .
' X, percent acetylation ofpUTKAT, with other values normalized to it .
1 NL, nonlinear acetylation of CAM approaching 100% .
Cell lines
Plasmids JY J558 Hela CV1 (COs)
pUTKAT X` X X X
RTK lox lox 20X NLt
BP800 0.1X 0.04X O .IX O.1X
BP8051 0 .05X 0.04X ND 0.1X
BT8057 1 .2X 1 .3X ND 0.5X1224
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shown) . Note, by way of contrast, thelarge stimulation of cat activity by thepRTK
plasmid (Fig . 6, lanes 1 and 2) .
Transfection in Lymphoid Cells Other Than T Cells .
￿
To more precisely define the tissue
specificity of the V88.1 promoter and determine whether it functions in cells of the
B lineage, two different B cell linesJY andJ558, which are, respectively, a human
EBVtransformed mature B cell and a murine B cell myelomawere examined . The
full-length V,88.1 promoter (BP800 ; Fig . 7, lanes3 and 4), the deleted version, which
still contains the TPE (BP8051 ; Fig . 7, lanes 5 and 6), and the TPE alone fused
to TK (BT8057; Figure 7, lanes 7and 8) were separately transfected into both mu-
rine and human B cell lines . The results are unequivocal ; in both non-T cell lines
the V,68.1 promoter proximal elements are inactive (Fig . 7 and Table II) . Further-
more, in contrast to the situation in T cells, the 230-bp TPE fragment does not fur-
ther stimulateTK promoter activity inB cells . Note that we have included theRTK
plasmid(Fig . 7, lanes 9and 10) in this experiment, which is several-fold more active
than theTK plasmid (Fig . 7, lanes 1 and 2) alone, thus indicating that it is possible
to activate the TK promoter in these cell lines (see also Table 1I) .
We conclude that the V,68.1 promoter contains sequences upstream of the start
site of transcription that impart aT lineage lymphoid-specific promoter selectivity.
The magnitude ofthe selectivity in murine lymphoid cells is 30-50-fold, and 20-30-
fold in human cells (Fig . 4 and Table f1) . This would seem to be enough to account
FIGURE 7 .
￿
V,Q8.1 promoter plasmids are inactive in either murine or human B cells. Transfec-
tions and CAT assays were carried out as described in Materials and Methods and the legend
to Fig . 3 B. J558 (A), a murine B cell line, or JY (B), a human EBVtransformed B cell line
were transfected with plasmids pUTKAT (lanes 1 and 2), BP800 (lanes 3and 4), BP8051 (lanes
5 and 6), BT8057 (lanes 7and 8), and pRTK (lanes 9 and 10) . Quantitation of the results by
scintillation counting are shown in Table II .DIAMOND ET AL.
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TABLE III
Quantitative Analysis of CATAssay Resultsfrom Transfected Vp8.1
Promoter Plasmids: Effect of RSV and IgHEnhancers in B and T Cells
The numbers shown are the percentages of acetylated CAM determined after
scintillation counting of the cut-out spots from TLC plates. Each point is the
average of two separate determinations that varied t 5To . For comparison,
data on the percentage acetylation with BP800 (EL-4, 12% ;J558, 0 .1 To Jur-
kat, 13% ; and JY, 1 .3%) and pUTKAT (EL-4, 2.4% ; J558, 2.5%; Jurkat,
5.2% ; and JY, 13%) in the cell lines tested are presented here.
The reaction of CAM to its acetylated form in this instance is nonlinear be-
cause of the strength of the interaction between the enhancer and the promoter,
thus underestimating the difference between EL-4 and J558 .
1 Nonlinear acetylation reaction.
for the T cell specificity of the rerranged endogenous V,B8.1 gene as determined by
Northern blot analysis of TCR-specific mRNA (16, 17).
IgH Chain Enhancer Does'not Stimulate V,68.1 Expression in B Cells.
￿
The striking re-
sult that demonstrated a T vs. B selectivity of the V,B8.1 promoter could be further
tested by taking advantage of the transcriptional enhancer elements that are active
in either lymphoid cells exclusively (H chain enhancer, IgHE; references 12, 13, and
43) or throughout all eukaryotic cells such as the RSV enhancer. To this end, either
the 1.0-kb murine IgHE-containing fragment (12) or the previously described RSV
enhancer (25) was placed 5' of both the TK and V,B8.1 gene promoters (see Table
I), and they were separately transfected in duplicate into both murine and human
B and T cells along with several other previously described plasmids . As shown in
Table III, the IgHE is very active in stimulating expression from the TK promoter
in all thecell lines tested, especially J558. The RSVenhancer is most active in human
cell lines, but substantial activity occurs in both murine cell lines tested (Table III).
A different story emerges when we examine the results of transfection into lym-
phoid cells of V,88.1 promoter plasmids containing the RSV or IgHE enhancer ele-
ments upstream of -800 (Table III). The V,e8.1 promoter is activated in T cells by
both of these elements, however, the results in B cells indicate a very feeble interac-
tion. These results arein sharp contrast to theexperimentswith TK promoter (Table
III), indicating that a TCR promoter is resistant to activation by these enhancers
in B cells.
Discussion
Several genes that are active in lymphoid cells have been characterized with re-
spect to expresson elements located 5' of the transcription start or in downstream
introns. The IgH and IgL gene loci contain both types of elements functioning to
regulate mRNA transcription. MHC class I or class II genes also contain 5' (34,
Plasmids EL-4 J558
Cell lines
Jurkat JY
IgHEBP800 70` 4.8 54 1 .9
RBP800 19 0.4 36 1 .5
IgHETK 21 61 24 20
RTK 21 15 .3 97 .51 601226
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44)or intronic regulatory elements (45). In addition, IFN-'Y is capableofup-regulating
the promoter-associated elements of MHC genes (44-47).
Studies ofthe DNA sequence elements that contribute to the regulation of TCR
expression have been more limited. Two reportsdemonstrated enhancer-like sequences
within the intron (47) of the human a chain locus or 3' of the C,a2 gene in the mouse
(CRE,(21,22). Luria et al. (47) also have presented evidence for tissue specificity of
a0.70-kb V, promoter fragment in T cells. Given that Tia subunit gene transcrip-
tion precedes (48) Ti a, we considered it particularly important to undertake the
present analysis. Our study of the V,68.1 promoter has demonstrated both the pres-
ence of an autonomous element referred to as TPE (Fig. 5), and thetissue-specificity
of the whole 0.80-kb fragment containing the promoter sequences (Figs. 4 B, and
6 and 7).
As a result of previous studies with TCR and MHC genes that localized expres-
sion elements within intronic sequences (see above), we firstconcentrated on defining
regulatory sequences downstream of the promoter within the intron between the
rearranged J of the V,e8.1 V gene and C,61 (see reference 49 for a map of this re-
gion). However, transfection analysis of plasmids containing the -4.0 kb of the in-
tron cloned in pUTKAT revealed no T cell-specific stimulation of theTK promoter
(data not shown) in Jurkat or EL-4 cells. Instead, we found that a 0.80-kb pro-
moter-containing fragment was active both in human and murine T cells (Fig. 4).
Sequence analysis of the V,38.1 promoter fragment revealed similarities only to
basal transcription elements (see Results), but no tissue-specific elements (TCR V «
and VR promoters, Ig V and V promoters, IL-2 promoter, MHC class I and class
II promoters, and IgH enhancer including the octamer) from adiverse set of genes
was located in this region. However, comparison of the sequences of the recently
described COE and the V,B8.1 promoter showed significant similarities, even though
it was ahuman/mouse comparison (see Results and reference 21). However, a coun-
terpart to the murine Y CO enhancer has not yet been identified in human. Neverthe-
less, acombinationofexpression elements that serveto enhance transcription is found
both in the IgH (23, 50) and IgL (14, 51) loci of the mouse or the globin (52, 53)
and H5 histone(54) loci in thechicken, which gives addedsignificance to thesimilarities
that were found in the sequence comparison of the V,a8.1 promoters 5' flanking DNA
with the murine COE (see Results).
To prove that the TPE is separate from and independent of the V,B8.1 proximal
sequences, we subcloned DNAupstream of -45 5' to the TK promoter in pUTKAT,
for example, as shown by BT8051 . In this series of experiments we demonstrated
that the TPE could confer upon the TK promoter T cell-specific expression, and
that as little as 230 by was required. Interestingly, DNA between -445 and -510
seemed to act to repressthe TPE (Fig. 4 B). This small DNA element is also capable
of repressing the TPE when the V,Q8.1 promoter proximal signals are used (i.e.,
BP8045 vs. BP8051; Fig. 4 A). Such "negative" activity has been observed in the
promoters of MHC class I genes (55), IFN-,(3 (42) IFN-a (56), andthe IgH enhancer
(57). The molecular basis for the negative influence of this sequence remains to be
determined.
Thesequence shown, by Anderson et al. (AGTGAT/CG/ATCA) (37), to be common
to many murine VR promoters as well as V,a8.1 (earlier pointed out by Siu et al. [20],
for V,08 promoters as part of a larger 16-bp region of similarity) is not obligatoryDIAMOND ET AL.
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forthe function of the TPE describedherein. In fact, the plasmids BP350 or BP045
are very similar in their expression properties in T cells, even though BP350 con-
tains thedecanucleotide whereasBP045 does not. Earlierstudies ofthis region using
the DNAse I footprint technique (49) localized a segment of 23 by protected by ex-
tracts from lymphoid and nonlymphoid cells. Based on the nucleotide sequence,
acandidate for the protein responsible for this observed protection is the transcrip-
tion factor AP-1, which is found in most eukaryotic cells (see Results and Fig. 1 A).
Thus, the T cell lineage specificity of this interaction remains to be determined.
Using the above transient transfection methods we also made a series of observa-
tions concerning the fine specificity of V,e8.1 expression in lymphoid cells. We found
that none of the plasmids driven by the V#8.1 promoter or TPETK constructs that
were preferentially expressed in T cells were active in B cells (Fig. 7). More impor-
tantly, using either a lymphoid-specific enhancer active in B and T cells (50) or a
ubiquitous functional enhancer (RSV), we were unable to activate the V88.1 pro-
moter in B cells (although activation occurred in T cells; Table III). In a similar
study of V, promoter specificity (50), it was found that enhancer-activated expres-
sion of aV, promoter does not occur in fibroblasts or EL-4 cells. Similarly, the regu-
lated T cell-specific IL-2 promoter could not be activated by an enhancer in non-T
cells (26, 58).
The possible implications of these results for transcriptional specificity and the
control of rearrangement of receptor genes in B and T cells should be considered.
Several types of evidence have accumulated that demonstrate that V, genes (59),
which are either unrearranged or specifically rearranged, are restricted in expres-
sion to B cells. To date, only transcripts arising from non-V start sites within the
IgH locus have been found in T cells (60-62).3
Circumstantial evidence from chromatin accessibility studies (66, 67) highlights
the role of DNAse I-accessible chromatin as a factor in the process of gene rear-
rangement. These arguments have been formalized by Alt and his colleagues (4,
68-70) by a careful analysis of an artificial recombination substrate in B and T cells.
They have found that increased transcription is associated with substrate rearrange-
ment, and significantly that TCR V region gene segments (Dg andJ/3) can recom-
bine appropriately in B cells. Furthermore, a Vp-DOJa-IgH enhancer recombina-
tion substrate undergoes Do to Ja rearrangements in both B and T cells, but only
undergoes Va to DJO rearrangements in T cells. These findings demonstrated that
the IgH enhancer was sufficient for Dojo rearrangements but that elements associated
with the VS (possibly the promoter) controlled tissue-specific V3 to DJO re-
arrangement (L. Ferrier and F. W. Alt, personal communication).
Given the correlation between transcription and rearrangement, ourdata suggest
that the reason for the inactivity of the substrate in B cells is the lack of transcrip-
tional activity from the Va promoter (see Fig. 7, A and B). Experiments in cultured
B and T cells with recombination substrates utilizing the V,B8.1 promoter could
directly test the hypothesis that rearrangement is dependent upon transcription of
the utilized V gene. More important would be to determine whether the activity
of the TPE in conjunction with downstream transcriptional start signals would be
s An example exists in the literature (63-65)of a V gene transcribed in a T cell tumor afterrear-
rangement caused it to fuse with part of theJ~Ca locus on chromosome 14. In this case, expression
elements from the newlyjuxtaposed locus may have overridden the normal control elements 5' of the
V, promoter in these morphologically transformed human T cell tumors.1228
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adequate to activate rearrangement within a recombination substrate. Finally, ex-
periments using cell fusions of B and T cells followed by assay of either the endoge-
nous or introduced V0 promoters for expression would help determine whether there
exists an inhibitory substance in B cells that extinguishes expression ofspecific TCR
promoters.
Summary
We have characterized the sequence contribution ofDNA 5' of a functionally rear-
ranged TCR promoter (V,88.1) on its T lineage-specific expression through the use
of the chloramphenicol acetyl-transferase (CAT) reporter gene. A 230-bp fragment
located 570 by upstream of the determined transcription start site of the V,68.1 pro-
moter confers a T lineage specificity of expression to aheterologous promoter. The
inability of the V,68.1 promoter and its associated elements to function in B cells
suggests the existence of a mechanism to prevent inappropriate VS gene expression
in Bcells. Ofconsiderable interest is the fact that both aB cell-specific andanontissue-
specific enhancer element were incapableof stimulating significant expression ofthis
promoter in B cells. We discuss the implication of these results on the process of
rearrangement of both Ig and TCR genes, and the differentiation of the lymphoid
system .
We would like to acknowledge thecontributionsmade by DavidD. Mooreduring the course
of this work.
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